Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34610
Abstract: The phase 3 POLO study demonstrated a significant progression‐free survival (PFS) benefit and preserved health‐related quality of life (HRQOL) for active maintenance treatment with olaparib vs placebo in patients with metastatic pancreatic cancer and a… read more here.
Keywords: metastatic pancreatic; germline brca; pancreatic cancer; active maintenance ... See more keywords